Randal W. Scott - 14 May 2021 Form 4 Insider Report for Talis Biomedical Corp

Role: Director
Signature: /s/ Karen E. Flick, Attorney-in-Fact for Randal W. Scott
Issuer symbol: TLIS on OTC
Transactions as of: 14 May 2021
Net transactions value: +$202,650
Form type: 4
Filing time: 18 May 2021, 15:19:03 UTC
Next filing: 22 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TLIS	Common stock	Purchase	$91,440	+9,000		$10.16	9,000	14 May 2021	Direct	F1
transaction	TLIS	Common stock	Purchase	$111,210	+11,000	+122%	$10.11	20,000	17 May 2021	Direct	F2
holding	TLIS	Common stock						1,390,065	14 May 2021	By Thinking Bench Capital, LLC
holding	TLIS	Common stock						312,500	14 May 2021	By OG Family Trust, u/d/t May 30, 2014

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This purchase was executed in multiple purchases at prices ranging from $10.03 to $10.25. The price reported above reflects the weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2	This purchase was executed in multiple purchases at prices ranging from $10.00 to $10.15. The price reported above reflects the weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Content

This purchase was executed in multiple purchases at prices ranging from $10.03 to $10.25. The price reported above reflects the weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.

This purchase was executed in multiple purchases at prices ranging from $10.00 to $10.15. The price reported above reflects the weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.